Company news
Viatris Inc. (NASDAQ:VTRS) news
Viatris Inc. news releases on 6ix. Latest, May 2, 2024: Viatris to Participate in the BofA Securities 2024 Health Care Conference
Press releases — page 3
Viatris to Participate in the BofA Securities 2024 Health Care Conference
May 1, 2024
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
April 30, 2024
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
April 15, 2024
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
April 14, 2024
Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States
March 31, 2024
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
March 26, 2024
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
February 27, 2024
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
February 27, 2024
Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results
February 4, 2024
Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders
December 14, 2023
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer
December 14, 2023
Viatris to Participate in the Jefferies London Healthcare Conference
November 13, 2023
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
November 12, 2023
Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]
November 6, 2023
Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance
October 29, 2023
Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row
October 22, 2023
Rajiv Malik to Retire as President of Viatris Effective April 1, 2024
October 19, 2023
Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking
October 17, 2023
Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023
October 9, 2023
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA
September 30, 2023
Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g.,...
September 26, 2023
Viatris Named to TIME's World's Best Companies 2023 List
September 11, 2023
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV
September 4, 2023
Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
August 6, 2023
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
August 6, 2023
Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
July 30, 2023
Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023
June 27, 2023
Viatris Named to USA Today's Inaugural List of America's Climate Leaders 2023
May 29, 2023
Viatris Announces Appointment of Leo Groothuis to Company's Board of Directors
May 21, 2023
Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year
May 21, 2023
Viatris to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
May 16, 2023
Viatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine
May 15, 2023
Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
May 7, 2023
Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting
April 23, 2023
Viatris to Report First Quarter 2023 Financial Results on May 8, 2023
April 11, 2023
Viatris Wins Summary Judgment in New York Securities Class Action
March 30, 2023
Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance
February 26, 2023
Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023
February 26, 2023
Viatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
February 14, 2023
Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
January 8, 2023
Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division
January 2, 2023
Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors
December 28, 2022
Viatris Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference
December 22, 2022
Viatris Announces Donations Totaling $1 Million to Provide Aid Supporting Access to Healthcare, Food Security and Water Stewardship
December 13, 2022
Viatris Announces Approval of Emissions Reduction Targets by the Science Based Target initiative (SBTi)
December 13, 2022
Viatris Completes Biosimilars Transaction with Biocon Biologics
November 28, 2022
Biocon Biologics Completes Acquisition of Viatris' Global Biosimilars Business
November 28, 2022
Viatris Named U.S. In-House Legal Team of the Year for Intellectual Property Litigation by LMG Life Sciences
November 17, 2022
Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent
November 9, 2022